News >

Nanus Discusses Importance of Neoadjuvant and Adjuvant Care in RCC

Angelica Welch
Published: Wednesday, May 30, 2018

David M. Nanus, MD

David M. Nanus, MD
The inclusion of neoadjuvant and adjuvant therapy in the treatment of patients with renal cell carcinoma (RCC) may reduce the risk of recurrence after surgery, said David M. Nanus, MD. Specifically, tyrosine kinase inhibitors (TKIs) and immunotherapy are showing benefit as adjuvant treatment options for patients with high-risk disease.

, Nanus, a medical oncologist at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discussed the promise of immunotherapy and the continued role of surgery in the treatment in RCC.

OncLive: Can you discuss the issue of neoadjuvant and adjuvant therapy in patients with kidney cancer?

Nanus: There have been many studies over the years, dating back 3 or 4 decades, trying to improve the outcomes for patients with renal tumors. These are generally large tumors that have invaded the vena cava that have a higher risk of relapse after surgery. Can we do anything to reduce that risk of relapse? For the longest time, we had no benefit—meaning that all of these randomized trials never showed an improvement in OS. Many of these studies are from the cooperative groups, specifically studies with sunitinib, pazopanib (Votrient), and sorafenib (Nexavar). 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication